Retinoids In Dermatology

Retinoids are valuable drugs in the dermatologic armamentarium, being employed in daily clinical practice. The text provides an in-depth update on the latest thinking on pharmacology, clinical use, side effects, and follow-up of retinoid therapy in dermatology; it also addresses topics related to retinoid use in special circumstances, such as vulnerable populations, concomitant surgery, and aesthetic procedures. CONTENTS: The background of retinoids * Mechanism of action of vitamin A * Mechanism of action of topical retinoids * Mechanism of action of isotretinoin * Mechanism of action of acitretin * Mechanism of action of bexarotene * Mechanism of action of alitretinoin * Effects of retinoids at the cellular level (differentiation, apoptosis, autophagy, cell cycle regulation, and senescence) * Effects of retinoids at the systemic level * New aspects of isotretinoin teratogenicity * Mucocutaneous side effects * Ophthalmologic side effects * Musculoskeletal side effects * Neurologic side effects * Psychiatric side effects * Gastrointestinal side effects * Endocrine and metabolic side effecs * Other systemic side effects: Cardiovascular, pulmonary, otolaryngorhinologic, genitourinary, renal, and immunologic * Retinoids in acne * Retinoids in hidradenitis suppurativa/acne inversa * Retinoids in rosacea * Retinoids in hair disorders * Retinoids in psoriasis * Retinoids in keratinization disorders * Retinoids in antiaging therapy * Retinoids in other skin diseases * Retinoids in lymphoma * Retinoids in cutaneous chemoprophylaxis * Guide to good clinical practice for vulnerable populations (infancy, childhood, fertile period, elderly) * Retinoids and concomitant surgery * Retinoids and concomitant aesthetic procedures * Laboratory and clinical follow-up * Teratogenicity and registry programs * Management of vitamin A and retinoid side effects * Future and novel unexplored indications of retinoids Published in association with the Journal of Dermatological Treatment.

This up-to-date reference describes how retinoids and carotenoids function in the skin and how they can be utilized to prevent and treat a wide variety of skin diseases, as well as advance biomedical research in relation to cancer treatment and immunology. Providing an in-depth update on the pharmacology, pharmacodynamics, and new applications of

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you’re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You’ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor. Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions. Covers the best uses for new biologic therapeutics. Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors. Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols. Features a highly detailed, disease-specific index, as well as purchase information for major drugs. Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.

Back for a new edition, Zoe Draelos' outstanding resource to cosmetic dermatology again provides a highly-illustrated, clinical guide to the full range of cosmetic skin treatments. Bringing together experts from research, industry, surgery and practice, it is structured in four distinct parts for easy navigation by the busy clinician: Basic Concepts - giving an overview of the physiology pertinent to cosmetic dermatology and the delivery systems by which treatments can take effect; Hygiene Products - evaluating cleansing and moisturising products; Adornment - looking at aesthetic techniques such as cosmetics, nail protheses and hair treatment; Antiaging - ie, injectables, resurfacing and skin contouring techniques, and the rapidly growing area of Cosmeceuticals. With over 300 high-quality images and key summary boxes throughout, this new edition incorporates the newest procedural innovations in this rapidly developing field. Perfect for all dermatologists, especially those specialising in cosmetic dermatology and whether hospital-based or in private practice, it provides the complete cosmetic regimen for your patients and will be an indispensable tool to consult over and over again.

With the aromatic retinoic acid analog Tigason oral and intravenous pharmacokinetic studies have been performed in 5 normal volunteers. Simultaneous fitting of single i. v. and oral data to a three-compartment model assuming first-order absorption was possible. Using Nonlin parameter estimates of the single-dose data, one is able to predict the decline in plasma levels of parent drug following cessation of a 10 days multiple dosing regimen up to 24 hours. The model is however unable to predict a phase of prolonged elimination observed beyond 24 hours. Moreover in 5 patients, who underwent chronic therapy (8-15 months), substantial plasma levels of both unchanged drug and main metabolite (corre sponding carboxylic acid) were observed up to 140 days after cessation of the therapy. An apparent half-life of elimination of 80-100 days can be calculated. The drug appears to be stored at some yet unknown storage site. Investigation of metabolism of Tigason in rats and humans revealed 19 different bio transformation products thus far, most of them appearing in the urine in low amounts (20010 of dose). A few of them (mainly the acid Ro 10-1670) after conjugation to glucuronic acid are excreted in the bile in high amounts (60-80% of dose). No drug appeared unchanged in the excreta after i. v. administration to rats. References 1. Bollag W (1971) Effects of vitamin A acid (NSC-122758) on transplantable and chemically-induced tumors. Cancer Chemother Rep 55:53-58 2.

Cosmeceuticals are ingredients or products that provide cosmetic and therapeutic benefits and which can be obtained without a prescription. They are one of the fastest growing segments in the personal care product market. Even in the worst economic climate, sales of cosmetics remain robust. Beauty enhancers are our best means of feel-good escapism, and we are not about to give them up. The ingredients, sales locations, and the regulation of sales are dynamic aspects of the industry. Here we give you a heads-up on where the market is going so you can make strategic decisions for your practice. This book will give you an understanding of facial cosmeceuticals examining the needs of the face, moisturizer formulation, noninvasive testing, and clinical evaluation to establish efficacy. It sheds light on topics such as the delivery mechanisms of active ingredients, vitamin A and C and other antioxidants, growth factors and stem cells, peptides, or amino acids. Topics also include the use of cosmeceuticals for the treatment of acne, rosacea, and hair loss and for hair care as well as the treatment of scars and cosmeceuticals for sun protection and protection from pollution. It also covers aspects of nutraceuticals and diets for healthy skin.

The impact of the retinoids in clinical practice has primarily been in dermatology. When Dr Werner Bollag began his basic research and screening programme in the early 1960's, the expectation was that the retinoids would have a major impact on oncology. However, the laboratory and clinical experiences of Bollag and his colleagues in Switzerland, Stuttgen and Orfanos in Germany, led to publications on both etretinates (Tigason) and isotretinoin (Roaccutane) in the years between 1972 and 1976 in the field of dermatology. In fact the first symposium on retinoid research held in Berlin in 1981 was almost entirely dermatological. A year later a retinoid workshop in Iowa was designed to provide a forum for dermatolog ists from the USA involved in specific protocols investigating oral retinoids. In the UK, research into the retinoids began rather later than in Continental Europe or in the USA, although Tigason was first marketed here. It was felt in late 1982 that as many dermatologists had relatively little experience with these compounds it would be appropriate to hold an International Symposium on retinoid therapy in the UK. Thus on 16-18 May 1983 in London, 37 speakers from 11 countries addressed an audience of 300, aminly UK, dermatologists. The scientific organizing committee consisted of but two persons Dr William Cunliffe of Leeds General Infirmary, representing the European Society of Dermatolo gical Research, and myself from Roche Clinical Research. The Symposium was held under the auspices of the ESDR and of Roche Products Limited.